Adam Cotton

Adam Cotton is a seasoned professional in the biotechnology sector with a diverse range of experience. Currently serving as a Board Observer at ONL Therapeutics and GentiBio, and as an Associate at Novartis Venture Fund, Adam focuses on investments in early-stage biotech companies. Previously, Adam held various roles, including Board Observer at Mediar Therapeutics, Hyku Biosciences, and FoRx Therapeutics, and was a Co-Founder of EpiBiologics, which specializes in protein degradation platforms. Consulting experience with RA Capital Management, along with a solid academic foundation, including a PhD in Chemistry and Chemical Biology from the University of California, San Francisco, and an MBA from the UNM Anderson School of Management, further enhances Adam's expertise in the field.